COCP vs. IMUX, ZIVO, XCUR, MGX, IRD, ANL, PDSB, CTOR, ASRT, and TELO
Should you be buying Cocrystal Pharma stock or one of its competitors? The main competitors of Cocrystal Pharma include Immunic (IMUX), ZIVO Bioscience (ZIVO), Exicure (XCUR), Metagenomi (MGX), Opus Genetics (IRD), Adlai Nortye (ANL), PDS Biotechnology (PDSB), Citius Oncology (CTOR), Assertio (ASRT), and Telomir Pharmaceuticals (TELO). These companies are all part of the "pharmaceutical products" industry.
Cocrystal Pharma vs.
Immunic (NASDAQ:IMUX) and Cocrystal Pharma (NASDAQ:COCP) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, media sentiment, community ranking, analyst recommendations, earnings and valuation.
Cocrystal Pharma is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.
In the previous week, Immunic had 13 more articles in the media than Cocrystal Pharma. MarketBeat recorded 16 mentions for Immunic and 3 mentions for Cocrystal Pharma. Immunic's average media sentiment score of 0.94 beat Cocrystal Pharma's score of 0.90 indicating that Immunic is being referred to more favorably in the media.
Immunic received 91 more outperform votes than Cocrystal Pharma when rated by MarketBeat users. However, 77.42% of users gave Cocrystal Pharma an outperform vote while only 66.09% of users gave Immunic an outperform vote.
Cocrystal Pharma's return on equity of -94.62% beat Immunic's return on equity.
51.8% of Immunic shares are held by institutional investors. Comparatively, 6.7% of Cocrystal Pharma shares are held by institutional investors. 3.0% of Immunic shares are held by insiders. Comparatively, 28.1% of Cocrystal Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Immunic currently has a consensus price target of $11.60, suggesting a potential upside of 1,210.29%. Cocrystal Pharma has a consensus price target of $7.00, suggesting a potential upside of 334.78%. Given Immunic's stronger consensus rating and higher probable upside, analysts clearly believe Immunic is more favorable than Cocrystal Pharma.
Immunic has a beta of 1.48, indicating that its share price is 48% more volatile than the S&P 500. Comparatively, Cocrystal Pharma has a beta of 2.15, indicating that its share price is 115% more volatile than the S&P 500.
Summary
Immunic beats Cocrystal Pharma on 10 of the 16 factors compared between the two stocks.
Get Cocrystal Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for COCP and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cocrystal Pharma Competitors List
Related Companies and Tools
This page (NASDAQ:COCP) was last updated on 6/11/2025 by MarketBeat.com Staff
